[1] Guidelines for referral and management of systemic lupus erythematosus in adults.American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines.Arthritis Rheum,1999,42:1785-1796. [2] van Vollenhoven RF.Dehydroepiandrosterone in systemic lupus erythematosus.Rheum Dis Clin North Am,2000,26:349-362. [3] Amano H,Morimoto S,Kaneko H,et al.Effect of intravenous cyclophosphamide in systemic lupus erythematosus,relation to lymphocyte subsets and activation markers.Lupus,2000,9:26-32. [4] Ortmann RA,Klippel JH.Update on cyclopho-sphamide for systemic lupus erythematosus.Rheum Dis Clin North Am,2000,26:363-375. [5] 王津生,李学平,冒长峙综述.新型免疫抑制剂霉酚酸酯在皮肤科的应用前景.中华皮肤科杂志,2001,34,76-78. [6] Burt RK,Marmont A,Schroeder J,et al.Intense immune suppression for systemic lupus-the role of hematopoietic stem cells.J Clin Immunol,2000,20:31-37. [7] Zandman-Goddard G,Shoenfeld Y.Novel approaches to therapy for systemic lupus erythematosus.Eur J Intern Med,2000,11:130-134. [8] Sharp JT,Strand V,Leung H,et al.Treatment with leflunomide slows radiographic progression of rheumatoid arthritis,results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis.Lefluno-mide Rheumatoid Arthritis Investigators Group.Arthritis Rheum,2000,43:495-505. [9] Gladmann DD,Urowitz MB,Kagal A,et al.Accurately describing changes in disease activity in systemic lupus erythematosus.J Rheumatol,2000,27:377-379. [10] Gladman D,Ginzler E,Goldsmith C,et al.The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.Arthritis Rheum,1996,39:363-369. [11] Hahn BH.Systemic lupus erythematosus.In,Fauci AS,ed.Harroson′ s principles of internal medicine.14th ed.New York,McGraw-Hill,1998.1874-1880. |